With increasing time since diagnosis, only the severe infections continued to cause symptoms.
The loss of activity is equivalent to 15% of the US population becoming completely immobile for 1 day.
Adult COVID-19 patients also infected with the flu are 4 times more likely to need mechanical ventilation and 2.4 times more likely to die.
The roadmap offers a powerful opportunity to leverage advances in vaccine science to better protect against influenza, including pandemic flu.
The Influenza Vaccines Roadmaps Initiative newsletter highlights recent news, research, and events pertaining to influenza vaccine R&D.
A database of novel vaccine candidates that are designed to provide broader and more durable protection against influenza viruses.
Help support our work on influenza. Advance the work of CIDRAP in public health preparedness and emerging infectious disease response.
Receive the latest infectious disease information.
(CIDRAP News) The Centers for Disease Control and Prevention (CDC) recently released a set of standards for public health preparedness capabilities to help state and local public health agencies set priorities and strategies in an age of budget-cutting.
Apr 12, 2011
(CIDRAP News) A team of US researchers recently added to the evidence that humans can and do produce antibodies that target a wide range of influenza strains, though how the findings can be exploited in the quest for a "universal" flu vaccine remains to be seen.
(CIDRAP News) Flu indicators in the United States and other Northern Hemisphere locations continue to plummet, with global surveillance showing only a few active areas in tropical and Southern Hemisphere locations that will soon be approaching their flu season.
Apr 6, 2011
Apr 4, 2011
(CIDRAP News) – Flu activity in the United States continues to tail off, though newly reported pediatric deaths were twice as high as the week before, the US Centers for Disease Control and Prevention (CDC) said today.
The percentage of deaths from pneumonia and flu, however, remained above the epidemic level, the agency said.
(CIDRAP News) – The US government today announced the award of a $231 million, 5-year contract to an Australian company for advanced development of a single-dose, long-acting influenza drug in the neuraminidase inhibitor class.
The contract was awarded to Biota Scientific Management Pty, Ltd., of Melbourne, according to the Biomedical Advanced Research and Development Authority (BARDA), part of the Department of Health and Human Services.
Mar 30, 2011
(CIDRAP News) North Carolina health officials have reported a number of influenza B isolates with reduced sensitivity to oseltamivir (Tamiflu), a rare finding, but they say antivirals remain effective and there is no reason for clinicians to change their prescribing practices.
